Holen Sie sich die Stockscreener-App
163.13
0.55%
-1.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca PLC Agencies, 2026 - OpenSecrets
Directors’ Deals: AstraZeneca’s Soriot in a major show of faith - Financial Times
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca Gets FDA Priority Review for IMFINZI Combo - grafa.com
AstraZeneca & Fevertree Drinks: Big director share deals - Investors' Chronicle
AstraZeneca gains EU approval for asthma drug, boosting growth outlook with strong pipeline and oncology focus - Pluang
Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum (NYSE:AZN) - Seeking Alpha
AstraZeneca (LSE:AZN) Wins EU Asthma Nod For Trixeo This Week: How Big Is Respiratory Opportunity? - Kalkine Media
AstraZeneca hails US priority review for Imfinzi for bladder cancer - London South East
AstraZeneca stock slips 1.91 percent as earnings estimates rise - AD HOC NEWS
Priority review for AstraZeneca's Imfinzi in bladder cancer - marketscreener.com
AstraZeneca stock gains 0.5 percent ahead of the open - AD HOC NEWS
AstraZeneca stock rises 0.5 percent ahead of the open - AD HOC NEWS
AstraZeneca PLC Agencies, 2021 - OpenSecrets
AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market? - Yahoo Finance
AstraZeneca’s New Asthma Care Trial Signals Long-Term Upside for Respiratory Investors - TipRanks
AstraZeneca stock heads into the open after a 2.84 percent drop - AD HOC NEWS
AstraZeneca stock heads into the open after a 1.20 percent drop - ad-hoc-news.de
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
AstraZeneca stock falls 2.65 percent after the close - AD HOC NEWS
AstraZeneca wins EU label expansion for Trixeo in asthma (AZN) - Seeking Alpha
AstraZeneca slides Wednesday, underperforms market - MarketWatch
AstraZeneca's Trixeo Secures Approval for Asthma in the EU - Yahoo Finance Australia
AstraZeneca LSE:AZN EU Drug Wins Put Cancer and Autoimmune Growth in Focus - kalkinemedia.com
AstraZeneca stock slips as Trixeo wins EU asthma approval - AD HOC NEWS
EU clears first triple-therapy asthma medicine from AstraZeneca (AZN) - Stock Titan
AstraZeneca (LSE:AZN) Pipeline Wins Put Valuation in Focus - Kalkine Media
AstraZeneca wins EU approval for Trixeo asthma inhaler - proactiveinvestors.co.uk
AstraZeneca PLC Announces Trixeo Approved In EU For Asthma - TradingView
AstraZeneca’s Trixeo Aerosphere Approved In EU For Asthma - DirectorsTalk Interviews
REGAstraZeneca PLCTrixeo approved in EU for asthma - TradingView
AstraZeneca stock heads into the open after a 0.08 percent fall - AD HOC NEWS
AstraZeneca stock gains 1.22 percent at the close - AD HOC NEWS
BreakingviewsCOMMENTARY: Big Pharma growth malady has a risky cure - Reuters
AstraZeneca stock gains as Deutsche Bank raises its target - AD HOC NEWS
AZN Historical Stock Prices & Daily Price Data | AstraZeneca PLC - Quiver Quantitative
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England - Insider Monkey
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
AstraZeneca PLC (AZN) Stock Analysis: Is A 27.75% Upside On The Horizon? - DirectorsTalk Interviews
Two favorable EU opinions for AstraZeneca - marketscreener.com
AstraZeneca’s Klygefa Recommended For EU Approval In Generalised Myasthenia Gravis - DirectorsTalk Interviews
AstraZeneca PLC (AZN.L) Stock Analysis: Unveiling a 26% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca PLC (Dinari Tokenized Stock)AZNStock Price & News - The Motley Fool
AstraZeneca PLC Agencies, 2024 - opensecrets.org
Long Wait Is Good Omen For AstraZeneca’s AVANZAR Lung Cancer Trial - insights.citeline.com
AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2 Positive Breast Cancer - marketscreener.com
AstraZeneca (AZN) CEO buys 60,000 shares in LON trade - Stock Titan
FDA Grants Priority Review to AstraZeneca's Efzimfotase - marketscreener.com
AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug - marketscreener.com
Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer - AstraZeneca
AstraZeneca Wins US FDA Priority Review for Hypophosphatasia Therapy - marketscreener.com
AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed - finance.yahoo.com
AstraZeneca advances Thursday, outperforms market - MarketWatch
AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts - finance.yahoo.com
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England - Reuters
Enhertu Approved by NICE for NHS, Impact on AstraZeneca (AZN) Un - gurufocus.com
Key facts: AstraZeneca PLC wins NHS access for breast cancer; pipeline could yield $10B - TradingView
AstraZeneca Shares Rise as J.P. Morgan Stays Overweight - Yahoo Finance
AstraZeneca shares oversold after trial flops and merger talk, says UBS - Proactive financial news
AstraZeneca's news flow next year could sustain drugs group beyond 2030, says leading bank - ca.finance.yahoo.com
AstraZeneca PLC : Gets a Buy rating from UBS - marketscreener.com
AstraZeneca PLC : JP Morgan keeps its Buy rating - marketscreener.com
Dividend-linked share awards boost AstraZeneca (NYSE: AZN) CFO stake - Stock Titan
AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss - Yahoo Finance
AstraZeneca (AZN) chair buys 2,500 shares on LON - Stock Titan
AstraZeneca PLC Lobbyists, 2013 - OpenSecrets
AstraZeneca PLC (AZN) Stock forecasts - Yahoo Finance UK
1.13%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):